Theriva Biologics Inc (TOVX)
2.07
+0.08
(+4.02%)
USD |
NYAM |
Nov 04, 16:00
1.88
-0.19
(-9.18%)
Pre-Market: 08:46
Theriva Biologics Research and Development Expense (Annual): 14.31M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.31M |
| December 31, 2022 | 11.72M |
| December 31, 2021 | 7.80M |
| December 31, 2020 | 5.131M |
| December 31, 2019 | 11.08M |
| December 31, 2018 | 11.84M |
| December 31, 2017 | 18.78M |
| December 31, 2016 | 29.11M |
| December 31, 2015 | 32.91M |
| December 31, 2014 | 14.49M |
| December 31, 2013 | 6.507M |
| December 31, 2012 | 12.29M |
| December 31, 2011 | 3.34M |
| December 31, 2010 | 1.58M |
| Date | Value |
|---|---|
| December 31, 2009 | 0.9489M |
| December 31, 2008 | 4.644M |
| December 31, 2007 | 6.328M |
| December 31, 2006 | 2.666M |
| December 31, 2005 | 0.9461M |
| December 31, 2002 | 3.622M |
| December 31, 2001 | 6.000M |
| December 31, 2000 | 3.747M |
| December 31, 1999 | 3.422M |
| December 31, 1998 | 2.40M |
| December 31, 1997 | 3.70M |
| December 31, 1996 | |
| December 31, 1995 | 4.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
5.131M
Minimum
2020
14.31M
Maximum
2023
10.01M
Average
11.08M
Median
2019
Research and Development Expense (Annual) Benchmarks
| BioCardia Inc | 7.726M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Oragenics Inc | 15.49M |